These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 9049482)

  • 1. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J; Barrow BA; Levy JC; Turner RC
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B; Idowu K; Holst JJ; Creutzfeldt W; Nauck MA
    Exp Clin Endocrinol Diabetes; 1998; 106(2):103-7. PubMed ID: 9628239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ; Gallwitz B; Salmen S; Goetze O; Holst JJ; Schmidt WE; Nauck MA
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2719-25. PubMed ID: 12788879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J; Hylleberg B; Ng K; Damsbo P
    Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA; Meier JJ
    Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.